Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out what effects (good and bad) ceritinib
(Zykadia®) used in combination with docetaxel (Taxotere®) will have on participants and their
cancer. The results will help to determine the best safe dose of the combination of the
medications Ceritinib (Zykadia®) and docetaxel (Taxotere®) and to find out if this
combination of drugs will help people that have this type of Non-small Cell Lung Cancer
(NSCLC).
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute